JP Shaw

In charge of DMPK group for drug discovery services- In vivo PK/ADME studies In vitro ADME screens Bioanalysis (non-GLP) Serve as project team leader for LO program and as DMPK representatives for LI and LO programs; working closely with Medicinal Chemistry, Discovery Biology and Pharmacology groups support integrated projects

Built a productive and efficient DMPK group from ground up Directed and managed up to 15 scientists and technical staffs supporting Discovery, Preclinical Development and Clinical Development Set up cross-functional collaborations as part of the core teams for Research and Development programs

In vitro metabolism study of novel HIV protease inhibitors; interspecies scaling for intrinsic clearance; In vivo and in vitro drug-drug interaction studies Preclinical PK and ADME studies for various nucleotide analogs to support IND/NDA filing; Established in vitro screens for oral prodrugs; Established in vitro cell culture model for intestinal permeation studies; In vivo/in vitro correlation; Developed bioanalytical assays for clinical PK analysis Metabolite profiling for ADME studies in preclinical species Metabolite isolation and identification Prepare NDA/IND reports In vitro stability of oligonucleotides; Applied antisense/triple helix technology targeting HIV; Designed novel endonuclease inhibitors for influenza virus

Identification of novel transcription factors regulate IL-2 gene expression; transcriptional control of IL-2 in T-cells; IL-2 expression in transgenic mice.